Publication number |
CLPUB00730 |
Authors |
Vazquez-Lopez A.M., Tormo B.R.B., Alfonso M., Velandia A., Fernandez-Molina L.E., Giscombe R., Ansotegui I.J., Jeddi-Tehrani M., Cedeno M., Toledo A.L., Perez-Rodriguez R., Mellstedt H., Biberfeld P. |
Title |
Characterization of IOR C5 colorectal tumor associated antigen. |
Citation |
Inmunologia 14:130-132(1995) |
Abstract |
Established human colon cancer cell line SW1116 was used to generate ior
C5 monoclonal antibody (mAb) by standard hybridoma technique. By
immunohistochemical studies the antigen was abundant and strongly
expressed in the epithelium of the gastrointestinal tract, mainly the
small and large intestine, and the bronchus epithelial cell lining; no
reaction was observed in the other normal tissues studies. Glandular
epithelial derived tumors, especially colorectal cancers showed a more
variable and heterogeneous reactivity to the antibody. Enzymatic and
chemical treatments of colorectal cancer membrane extracts indicated that
the antigen recognized by this mAb is an O-linked glycoprotein
carbohydrate chain. Western blot studies on SW1116 cell membrane extracts
showed that the ior c5 mAb recognized a glycoprotein complex composed of a
major 145 kDa band and a minor 190 kDa band. The epitope recognized by
this mAb can also be found in a high molecular weight glycoprotein
obtained from normal colon. In blocking experiments using ior c5 and ior
c2 mAb (previously reported by us), it was shown that both mAbs compete for
the same antigen site, although ior C5 shows a higher blocking efficiency.
Additionally, ior c5 in contrast with ior c2 mAb, was capable of blocking
the recognition of 17-1A mAb by a pool of human anti idiotypic antibodies
generated agains 17-1A mAb. Since, 17-1A and ior c5 mAbs recognized
different antigens, the above result indicates that these anti idiotypic
antibodies recognize a non paratopic idiotype shared by both 17-1A and ior
c5 mAbs. The preferential staining of colorectal tumors and the
restricted reactivity in normal human adult tissues make ior c5 mAb an
eligible candidate for the radioimmunodetection of colorectal tumors.
|
Cell lines |
CVCL_C6UV; IOR-C5 |